Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
005 x 0053
Market cap well under $2m with KetaDash vans now on the streets, and demand for ketamine therapy increasing
Stocks drop, ketamine use increases
KetaDash could be doing booming business in 2023 for sure
Stress pushing people to ketamine therapy
That article shows Wall Street traders rushing to get ketamine IV treatments.
Ehave offers mobile ketamine vans -- KetaDash
They should drive one down to New York Stock Exchange
Wall Street traders using ketamine IV's
https://nypost.com/2022/10/05/stressed-wall-street-execs-flock-to-ketamine-clinic-for-therapy/
Therapy’s a trip for these Wall Street executives.
Wealthy stock traders are flocking to a Manhattan “ketamine clinic” that doles out the hallucinogenic drug in a lavish setting to treat depression, stress and burn-out syndrome, according to the psychiatrist who runs it.
The Jeff Ditzell Psychiatry center in the Financial District legally doses patients with the drug — best known as a psychedelic party favor — via IV drip for $750 a pop, Ditzell told The Post Wednesday.
“We see a lot of Wall Street traders,” Ditzell said, adding 30 to 40% of his clients work in the financial industry.
EHVVF $0.04 price target issued!
https://ludlowresearch.com/reports/?fbclid=IwAR2Xe1mOcR-XXyiKiKfGKvKqn4_eV8Z1_63j6cVY4x1t5UND6i-I-_JyFjQ
EHVVF clinical trials with FDA
Ehave $EHVVF clinical trials with #FDA https://t.co/h5WPQznvSd$CYBN $LVT $NEON $WESA $PHRX $TRYPF $TLRY $CBIS $CGC #clinicaltrials pic.twitter.com/VFZfEmbp7r
— Trader Madness (@TraderMadness) October 5, 2022
Market starting to improve
...if we can see rates cool off, and data start to come in weak, that could help restart to penny market with liquidity coming back in.
EHVVF using AI for mental health tech
Really excited about this merger and TPIA dividend situation. This company is going places.
TPIA moving up
Merger could be close and EHVVF owns big block of TPIA that's worth more then entire market cap of EHVVF right now!
S-4 filed with SEC
PSLY.com has filed their S-4 with SEC.
TPIA rocket is fueling up for blast off.
EHVVF owns a big equity stake in TPIA and may give that out as dividend to Ehave shareholders?
Ei.Ventures has also filed their 1-A so something is in the mix
https://www.benzinga.com/secfilings/22/09/29006124/ei-ventures-inc-form1-sa
Keeping eye on TPIA as canary in coal mine.
Exciting collaboration going on here
https://finance.yahoo.com/news/ehave-inc-announces-psychedelics-precision-130000745.html
Dog chit + dog chit = more dog chit
Tpia + ehvvf = ?
Who needs help solving it?
Ehave owns 9.7M shares TPIA
Was hoping to get some shares down low, but looks like its moving and maybe about to see merger deal come through.
Ehave owns approximately 9,793,754 shares of Mycotopia Therapies $TPIA
9,793,754 x .60 = $5.8M
EHVVF current market cap = $2M
https://www.otcmarkets.com/stock/ehvvf/security
EHVVF issued .04+ target
Ludlow Research initiates research opinion on Ehave $EHVVF with $0.04+ price target$EHVVF owns major equity stake in Mycotopia Therapies $TPIA, which is executing psychedelic stock merger pic.twitter.com/Ld1yrD28J1
— Ludlow Research (@LudlowResearch) September 21, 2022
EHVVF has huge equity stake in TPIA
...and TPIA stock is running.
Value of EHVVF stake in TPIA now way more then EHVVF entire market cap.
Load up!
DNA testing for psychedelics? That's not big that's HUGE! Wow
DNA testing for psychedelics could be big
I didn't even know they could do this, and could see many want to get a test done before starting psychedelic treatment programs.
San Fran Approves Psychedelic legalization
https://californiaglobe.com/articles/resolution-that-decriminalizes-psychedelic-drugs-passed-by-san-francisco-board-of-supervisors/
Recession gonna trigger lot of stress & anxiety
More population is messed up with stress and depression more stocks in this sector will get new eyes. On watch as possible play on recession and layoffs for post-COVID you could see lot of people just crack from the pressure and seek out alternative mental health solutions.
Like to see key resistance points break with volume before getting excited. Had some decent volume late last week.
Impressive chart we have here this morning. I have high hopes for this company they won't disappoint especially now with this recession.
Psychedelic stock $EHVVF Ehave Inc. #bullish outlook. It's a stress from recession play here! $DMT $LOBE $SILO $MSET $NOVA $CYBN $NUMI $OPTI $TRYP #pyschedelic #stress #anxiety pic.twitter.com/vycgE8QiTf
— Penny Whispers (@Peneewhispers) September 12, 2022
EHVVF upgraded on growing recession stress
The cargo mobile van in Miami will have a team of doctors and nurses traveling around Miami, more explanation may be required for that news to have an impact on Share Price,
Who is paying the doctors and nurses for example.
4:30p ET 6/1/2022 - Benzinga
Ehave Partners With Halugen Life Sciences To Create A Ketamine Precision Medicine Platform For Clinical Research
Ehave, Inc. (OTC Pink: EHVVF) is a leading healthcare services and technology company focused on progressing psychedelics to therapeutics by engineering novel compounds and new treatment protocols for treating brain health. They do so by leveraging clinical data in order to achieve the best results possible.
Entheon Biomedical Corp. (OTCQB: ENTBF) is a wholly-owned subsidiary of HaluGen Life Sciences Inc., a company that has developed a DNA testing and personalized psychedelic pre-screening platform that provides genetic, personal and familial insights to better inform the psychedelic experience, improving patient care while reducing side effects and risk. Therefore, HaluGen's genetic-based platform helps evaluate an individual's overall sensitivity and risk profile when using hallucinogenic drugs with test results within days.
Both companies have combined their efforts and the result is a new expanded psychedelics genetic testing panel for Ehave's subsidiary psychedelics company, KetaDASH. The device will analyze a series of relevant DNA biomarkers and use pre-screening mental health surveys to understand a given individual's risk and potential of adverse reactions with the use of ketamine.
The new device will provide results that will be, then, absolutely personal.
On the other hand, genetics can play a key role in determining how an individual may respond to psychedelic-assisted psychotherapy. Specifically, the gene mutation CYP2B6 can influence the metabolism of ketamine for the 10-20% of people that carry a specific variant. Similarly, the HTR2A gene mutation, present in nearly 20% of the population, can impact how a person responds to serotonin, which is the primary mechanism of action for serotonergic psychedelics such as psilocybin, LSD and DMT.
It is expected that precision medicine will provide KetaDASH with the ability to tailor the treatment based on an individual or sub-groups variability in genes and lifestyle choice.
As Ehave CEO Ben Kaplan put it, "The benefit of the psychedelic profile is that it will enable the individuals and healthcare professionals at KetaDASH to personalize psychedelic therapy by providing an individual's metabolic status for ketamine with their CYP2B6 genotype."
This is a point of view shared by Entheon CEO Timothy Ko. "We believe that personalization will become an increasingly important feature of the psychedelic therapeutics landscape."
Photo Courtesy of Pixabay
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.”
Sooooo nice!!!
Strong? What's strong?
Only thing strong w/ this pos is the amount of dilution...lol
Very good to see EHVVF gaining new attention for the company's important advancements in the emerging field of mental health and wellness.
From the Roth Capital news:
Ehave Inc (OTC:EHVVF), a leading healthcare services and technology company, announced on April 19 that its mobile application platform MetaHealthU will enter the market with a focus on determining the cause and finding a possible cure for hallucinogen-persisting perception disorder (HPPD). Ehave pioneered HPPD research efforts by initiating a series of studies through its partnership with the University of Melbourne to gather data and biomarkers to target the disease. As psychedelics become more widely accepted, Ehave's MetaHealthU data and biomarkers will help medical and mental health professionals diagnose whether an individual is genetically predisposed to suffer from HPPD. One of the components of MetaHealthU is its digital wallet connectivity with the blockchain, which allows users to aggregate and share their health records securely and seamlessly. The pilot study will begin at the end of the second trimester or the beginning of the third trimester.
Roth Capital Reveals Top Psychedelic Picks in New Industry Report https://prnewswire.com/news-releases/roth-capital-reveals-top-psychedelic-picks-in-new-industry-report-301529820.html
Nice bounce off the lows today on almost 2x its 10-day average volume... $EHVVF
$EHVVF Roth Capital Reveals Top Psychedelic Picks in New Industry Report https://prnewswire.com/news-releases/roth-capital-reveals-top-psychedelic-picks-in-new-industry-report-301529820.html
#Psychedelics #MentalWellness #BrainHealth #Pharmaceuticals #FrontPageStocks
prnewswire.com
$EHVVF Bounce time now! LETS GO!
$EHVVF mentioned in this article with some of the big boys... Nice exposure.
$EHVVF is covered here: Roth Capital Reveals Top Psychedelic Picks in New Industry Report
April 21, 2022 (PR Newswire)
FN Media Group Presents Microsmallcap.com Market Commentary
Investment banks are continuing to release positive coverage for psychedelic stocks and the latest report from Roth Capital is no exception. On April 19, Roth Capital analyst Elemer Piros issued an industry note outlining the significant upside potential of six psychedelic drug companies. Piros cited the positive results of psychedelic-assisted psychotherapy for the treatment of mental health, which "isn't a perfect solution, but for many the response rate is remarkable." The analyst believes the psychedelic medicine market could exceed $500 billion, which is more than the annual US prescription drug spend, creating an extraordinary opportunity for companies like Cybin Inc. (NEO:CYBN) (NYSE:CYBN), which was among the six companies included in the Roth Capital report, as well as Numinus Wellness (TSX:NUMI) (OTCQX:NUMIF), Ehave Inc (OTC:EHVVF), Atai Life Sciences N.V. (NASDAQ:ATAI), and Enveric Biosciences Inc (NASDAQ:ENVB).
Cybin Inc. (NEO:CYBN) (NYSEAmerican:CYBN) is transforming the landscape of mental health treatment by combining novel psychedelic molecules with controllable drug delivery systems through its proprietary deuterated process, creating patent-protected, commercially scalable drug candidates.
Cybin recently announced that it has selected Clinilabs Drug Development Corporation, a global, full-service contract research organization with deep expertise in central nervous system drug development, to carry out its Phase 1/2a clinical trial of Cybin's CYB003, a proprietary deuterated psilocybin analog. CYB003 will be the first psilocybin analog to be evaluated in Phase 1/2a development for the treatment of major depressive disorder (MDD). Through multi-species preclinical studies, CYB003 demonstrated significant advantages over classic psilocybin including, faster onset of action, shorter duration of effect, less variability in plasma levels, and potentially better tolerability for an overall better outcome for patients.
"We are delighted to partner with the Clinilabs team as we progress this important program toward a first-in-human Phase 1/2a trial. Clinilabs brings a unique combination of scientific and operational experience and deep expertise in clinical research across a range of psychiatric, neurological and substance use disorders," said Cybin CEO Doug Drysdale. "Clinilabs is ideally suited to help us accelerate the regulatory pathway for this promising treatment candidate and ultimately, to effectively treat those suffering with MDD."
Cybin recently completed its IND-enabling in vivo preclinical studies of CYB003 to support the advancement toward an investigational new drug (IND) filing with the U.S. Food and Drug Administration (FDA) for the Phase 1/2a clinical trial. The company intends to submit an IND to the FDA in Q2 2022 and expects to initiate the Phase 1/2a trial in mid-2022.
Cybin is also currently developing CYB004 to treat anxiety. On April 13, the company released encouraging CYB004 preclinical data, which may support the use of inhalation as a viable and well-controlled delivery system for therapeutic psychedelics. The pharmacokinetic study evaluates its proprietary deuterated dimethyltryptamine (DMT) molecule, CYB004, which is administered by inhalation. Inhaled CYB004 showed significant advantages over intravenous and inhaled DMT, such as longer duration of action and improved bioavailability. The pilot study is expected to launch in the third quarter of this year.
For more information about Cybin Inc (NYSE:CYBN) (NEO:CYBN), click here.
Biopharma Companies Have Cash to Develop New Treatments
Atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, announced on March 30 its financial results for the fourth quarter and full year 2021. Highlights included positive Phase 2b data with COMP360 from a breakthrough trial in treatment-resistant depression (TRD). Eight new programs had been added to the company's platform since January 2021, bringing a total of 13 drug discovery and development programs and four enabling technologies to date. atai ended 2021 with a strong cash position of $362 million. At least 14 drug and enabling technology development catalysts are planned over the next two years, including PCN-101 Phase 2a proof-of-concept data in TRD.
Ehave Inc (OTC:EHVVF), a leading healthcare services and technology company, announced on April 19 that its mobile application platform MetaHealthU will enter the market with a focus on determining the cause and finding a possible cure for hallucinogen-persisting perception disorder (HPPD). Ehave pioneered HPPD research efforts by initiating a series of studies through its partnership with the University of Melbourne to gather data and biomarkers to target the disease. As psychedelics become more widely accepted, Ehave's MetaHealthU data and biomarkers will help medical and mental health professionals diagnose whether an individual is genetically predisposed to suffer from HPPD. One of the components of MetaHealthU is its digital wallet connectivity with the blockchain, which allows users to aggregate and share their health records securely and seamlessly. The pilot study will begin at the end of the second trimester or the beginning of the third trimester.
Enveric Biosciences Inc (NASDAQ:ENVB), a neuroscience company developing next-generation psychedelic-inspired mental health drugs, has filed a provisional patent application based on new findings by the company. The patent application and claimed drug candidates fall under Enveric's EVM201 second-generation psychedelic-derived drug development program, with an initial target indication of Cancer-Related Distress (CRD) and the possibility of being expanded to other mental health indications. Enveric reported a comprehensive net loss of $48.8 million for the year ended December 31, 2021, compared to a net loss of $7 million a year ago. The company had cash and cash equivalents of $17.4 million and working capital of $15.3 million at the end of 2021. After December 31, 2021, the company has raised an additional $10 million and plans to use the funds to advance its novel drug discovery platform, strong intellectual property portfolio, and growing portfolio of promising drug candidates.
On April 12, Numinus Wellness (TSX:NUMI) (OTCQX:NUMIF) announced it will acquire Novamind in an all-share transaction for total consideration of approximately C$26.2 million. Following the transaction, the combined company will operate 13 wellness clinics. Numinus will become one of North America's leading providers of psychedelic therapies, leading its peer group in revenue with approximately C$10 million in annual pro-forma revenue based on the past four quarters. For the second quarter, Numinus's revenue grew 240% year-over-year to $800,000. The company achieved a gross margin of 29.1% in the quarter, compared to 6.5% in the prior-year quarter, due to a greater proportion of higher-margin services provided in wellness clinics. Gross profit amounted to $228,759 during Q2 2022, an increase of 349% year-over-year. Numinus ended the quarter with a strong cash position of $48.3 million.
Cybin recently published an international patent application covering inhalation delivery methods for multiple psychedelic molecules. The PCT application will allow Cybin to apply for IP protection for multiple inhaled forms of psychedelic molecules that the company is currently researching and developing.
DISCLAIMER: Microsmallcap.com (MSC) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MSC or any company mentioned herein. The commentary, views and opinions expressed in this release by MSC are solely those of MSC and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MSC and FNM for any investment decisions by their readers or subscribers. MSC and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. The Article and content related to the profiled company represent the personal and subjective views of the Author (MSC), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (MSC) has not independently verified or otherwise investigated all such information. None of the Author, MSC, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated twenty five hundred dollars by MSC, a non-affiliated third party to distribute this release on behalf of Cybin Inc
FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MSC and FNM undertake no obligation to update such statements. Media Contact: FN Media Group, LLC info@financialnews.com +1(561)325-8757
https://c212.net/c/img/favicon.png?sn=IO31809&sd=2022-04-21
View original content:https://www.prnewswire.com/news-releases/roth-capital-reveals-top-psychedelic-picks-in-new-industry-report-301529820.html
SOURCE Microsmallcap.com
$EHVVF volume looking good so far this morning. It's thin after 0.01, which is a resistance point on the chart.
$EHVVF testing resistance at 0.01 on the chart... RSI indicator almost at 50, still room to grow. Green and up almost 5%.
Ketamine is a promising new treatment option for many conditions due to how it affects the brain and how quickly it starts working. From individual treatment sessions to group meditation, KetaDASH offers various ketamine treatments in the comfort of your own home.
https://ketadash.com/
$EHVVF Bringing Psychedelic Medicine To The Masses Through Data
https://www.ehave.com/
Looking for updates on this partnership with Mycotopia...$EHVVF
“We are delighted to grow our partnership with Mycotopia through the expansion of our supply agreement,” says HAVN Life CEO, Tim Moore. “We welcome the opportunity to see our products reach a broader market and look forward to working with Ben and his team in their development of plant-derived, therapeutic treatment options that address global mental healthcare needs,” he adds.
$EHVVF trading low volume compared to its 10-day average volume 2 hours into the day...thin on both sides of the tape.
This could be revolutionary in the treatment of HPPD...
Ehave Inc (PK) (EHVVF) 0.011 +0.00075 (7.32%)
Volume: 77,820
Important developments are happening with EHVVF at this time as detailed in the recent company news below. The company have valuable therapy for the increasingly important field of mental health and wellness so it is very good to see that they are moving to secure key trademark protection. Also glad to see efforts being made to further enhance shareholder value with an uplisting of the stock to the higher OTCQB tier soon.
Ehave Inc. Files for KetaDash Trademark and to Uplist its Shares to the OTCQB
MIAMI, March 03, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it has filed application #90549575 on February 26, 2021 with the United States Patent and Trademark Office (USPTO) for a trademark on its KetaDASH brand name. The application has been accepted by the USPTO and will be assigned to an examining attorney. Ehave recently announced plans to launch open testing of its KetaDASH ketamine IV therapy in the second quarter using advanced vein technology. On March 1, 2021 Ehave successfully filed its application to uplist its shares on the OTCQB market.
The USPTO is the federal agency for granting U.S. patents and registering trademarks, and it registers trademarks based on the commerce clause of the Constitution (Article I, Section 8, Clause 3). The KetaDASH www.ketadash.com platform allows licensed ketamine clinics and patients who have been prescribed ketamine by a physician to administer the treatment at home intravenously. KetaDASH is a personalized mental care platform designed to instantly connect patients with highly skilled nurses to provide ketamine therapy at home under expert supervision. The platform has been strategically designed as a smart and intuitive dashboard from where patients and their associated nurses can get detailed insight on treatments. KetaDASH will soon be available on the App Store and Google Play Store.
Ben Kaplan, Chief Executive Officer of Ehave commented, “The application for a U. S. Trademark is a key step in protecting our valuable brand and psychedelic medicine assets, most notably KetaDASH.” Mr. Kaplan continued, “Looking toward the future, we see our KetaDASH brand as a major asset as we continue to seek new collaboration opportunities with partners and investors to develop psychedelic treatments for mental health and make them a commercial reality.”
Additional Ehave Inc. Information
We are truly grateful for the support of EHVVF shareholders! Please join the conversation on our Ehave supporter’s telegram group at https://t.me/EhaveInc.
The company posts important information and updates through weekly videos from the official company YouTube channel https://www.youtube.com/channel/UCnyW1mgMd0qmYkEMq3O6FWA.
Please follow Ehave on Twitter @Ehaveinc1
About Ehave, Inc.
Ehave, Inc. (EHVVF) is a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. Additional information on Ehave can be found on the Company’s website at: http://www.ehave.com.
Forward-Looking Statement Disclaimer
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website, http://www.sec.gov.
Contact: Ehave Inc
Media Inquiries: Gabe Rodriguez
Gabe@Ehave.com
Investor Relations:
Email: Ir@Ehave.com
Phone: (623) 261-9046
$EHVVF low volume compared to its 10-day average volume..Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced its MetaHealthU mobile application platform will focus on determining the cause and finding a possible cure for hallucinogen-persisting perception disorder (HPPD).
Followers
|
53
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2523
|
Created
|
02/27/17
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |